Crescent Biopharma Launches Underwritten Public Offering, Diluting Existing Shareholders
CBIO sits 67% above its 52-week low of $8.72 on light trading volume (0.2× avg).
Summary
Crescent Biopharma has commenced an underwritten public offering of ordinary shares and pre-funded warrants, with a 15% overallotment option. The size and price are not yet disclosed, but the offering is separate from the $200M at-the-market program filed on July 1. This follows the recent S-3 shelf registration and comes as the company reported Q2 cash of $171.6 million, down $17.6 million from Q1. The offering will dilute existing shareholders and signals a need for additional capital beyond the ATM. The involvement of multiple bulge-bracket banks suggests significant size, likely pressuring the stock. Terms will be set after marketing; watch for pricing details in the coming days.
At the time of this announcement, CBIO was trading at $14.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $422M. The 52-week trading range was $8.72 to $27.41. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.